Fusion polypeptides and preparation method and use thereof

A dual-target fusion polypeptide targeting GLP-1R and GHR addresses the limitations of single-pathway obesity treatments by simultaneously modulating multiple hormonal pathways, effectively regulating energy balance and reducing obesity-related risks.

WO2025237364A1 Publication Date: 2025-11-20PROSIT SOLE BIOTECH BEIJING
0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2025/095049
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-06-20
Filing Date
2025-05-15
Publication Date
2025-11-20

AI Technical Summary

Technical Problem

Current obesity treatments primarily target single hormonal pathways, failing to effectively regulate body energy balance and reduce obesity, as obesity is a multifactorial disease influenced by various hormones.

Method used

Development of a dual-target fusion polypeptide combining GLP-1 receptor (GLP-1R) and growth hormone receptor (GHR) fragments to simultaneously modulate multiple hormonal pathways, utilizing GLP-1 polypeptides and growth hormone proteins or variants thereof, with specific sequence homologies and mutations for enhanced efficacy.

Benefits of technology

The dual-target fusion polypeptide provides a comprehensive approach to regulate body energy balance, offering potential for significant weight loss and reducing obesity-related risks, such as cardiovascular disease and type 2 diabetes.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a fusion polypeptide, the fusion polypeptide targeting both GLP-1 receptors (GLP-1R) and growth hormone receptors (GHR). The present invention provides polynucleotides encoding the fusion polypeptide, vectors expressing the fusion polypeptide and / or comprising the polynucleotides, as well as cells expressing the polynucleotides and / or comprising the vectors. The present invention also provides methods of preparing the fusion polypeptide and use of the fusion polypeptide in the manufacture of a medicament. Also provided are methods of treatment and fusion polypeptides for use in therapy.
Need to check novelty before this filing date? Find Prior Art